TY - JOUR
T1 - Sex hormones and the risk of incident prostate cancer
AU - Daniels, Nicholas A.
AU - Nielson, Carrie M.
AU - Hoffman, Andrew R.
AU - Bauer, Douglas C.
N1 - Funding Information:
The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provided support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources (NCRR), and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580 , U01 AR45614 , U01 AR45632 , U01 AR45647 , U01 AR45654 , U01 AR45583 , U01 AG18197 , U01-AG027810 , and UL1 RR024140 . Presented in part and the annual meeting of the American Urological Association, Chicago, Illinois, April 26, 2009 (podium session presentation).
PY - 2010/11
Y1 - 2010/11
N2 - Objective: To assess whether sex hormone levels are associated with subsequent development of prostate cancer. Methods: A case-cohort study was conducted within the ongoing Osteoporotic Fractures in Men cohort study of community-dwelling men <65 years old recruited at 6 US clinical sites. After a mean follow-up of 4.7 years, all men with incident-confirmed prostate cancer and a random sample of the full cohort (subcohort) were selected for analysis: after excluding men with a history of prostate cancer and those who reported androgen or antiandrogen therapy at baseline, the resulting analytic sample comprised 275 cases and 1652 noncases with complete sex hormone measurements. Serum testosterone, estradiol, estrone, and sex hormonebinding globulin were assayed at baseline (prediagnosis) by gas chromatography combined with mass spectrometry. Associations between incident prostate cancer and each sex hormone were evaluated using Cox proportional hazards regression models adjusted for age, race, study site, body mass index, and person-time. Results: In the subcohort, the mean age was 73 years. Higher serum estrone was strongly related to an increased risk of prostate cancer: compared with men in the lower quartile, the risk of prostate cancer among those in the highest 3 quartiles (>24.9 pg/dL) was nearly 4-fold higher (adjusted heart rate = 3.93, CI: 1.61-9.57). Other sex hormones were not associated with the risk of prostate cancer. Conclusions: In this cohort of older men, higher estrone levels were strongly associated with an increased risk of incident prostate cancer. This association between estrone and prostate cancer risk needs to be clarified by further study.
AB - Objective: To assess whether sex hormone levels are associated with subsequent development of prostate cancer. Methods: A case-cohort study was conducted within the ongoing Osteoporotic Fractures in Men cohort study of community-dwelling men <65 years old recruited at 6 US clinical sites. After a mean follow-up of 4.7 years, all men with incident-confirmed prostate cancer and a random sample of the full cohort (subcohort) were selected for analysis: after excluding men with a history of prostate cancer and those who reported androgen or antiandrogen therapy at baseline, the resulting analytic sample comprised 275 cases and 1652 noncases with complete sex hormone measurements. Serum testosterone, estradiol, estrone, and sex hormonebinding globulin were assayed at baseline (prediagnosis) by gas chromatography combined with mass spectrometry. Associations between incident prostate cancer and each sex hormone were evaluated using Cox proportional hazards regression models adjusted for age, race, study site, body mass index, and person-time. Results: In the subcohort, the mean age was 73 years. Higher serum estrone was strongly related to an increased risk of prostate cancer: compared with men in the lower quartile, the risk of prostate cancer among those in the highest 3 quartiles (>24.9 pg/dL) was nearly 4-fold higher (adjusted heart rate = 3.93, CI: 1.61-9.57). Other sex hormones were not associated with the risk of prostate cancer. Conclusions: In this cohort of older men, higher estrone levels were strongly associated with an increased risk of incident prostate cancer. This association between estrone and prostate cancer risk needs to be clarified by further study.
UR - http://www.scopus.com/inward/record.url?scp=78149361038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78149361038&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2010.01.086
DO - 10.1016/j.urology.2010.01.086
M3 - Article
C2 - 20451981
AN - SCOPUS:78149361038
SN - 0090-4295
VL - 76
SP - 1034
EP - 1040
JO - Urology
JF - Urology
IS - 5
ER -